Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12171917 | 0.88 | NPC1 (0.66) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL1505310 | 0.87 | NPC1 (0.65) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL7323788 | 0.85 | CA1 (0.64) | NPC1RAB9AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL969326 | 0.85 | SMN1; SMN2 (0.56) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL13780884 | 0.85 | NPC1 (0.53) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL1505415 | 0.85 | NPC1 (0.57) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL967418 | 0.85 | SMN1; SMN2 (0.56) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL1505363 | 0.85 | NPC1 (0.53) | NPC1RAB9AHSD17B10TSHRALOX15 | |
| SCHEMBL7825137 | 0.83 | PLAU (0.66) | NPC1RAB9ATSHRALDH1A1KDM4E | |
| SCHEMBL4261704 | 0.83 | ALDH1A1 (0.55) | NPC1RAB9AHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | NPC1 856/4885RAB9A 1104/4885HSD17B10 2841/4885 |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | NPC1 856/4885RAB9A 1104/4885HSD17B10 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.